Международный форум по вопросам лечения хронического миелолейкоза
https://doi.org/10.17650/1818-8346-2007-0-2-76-79
Аннотация
С 14 по 16 сентября 2006 г. в Санкт-Петербурге состоялась международная конференция «5 лет гливека в России», посвященная различным вопросам лечения хронического миелолейкоза (ХМЛ).
Список литературы
1. Guilhot F.G., Roy L., Millot F. Update of first-line in chronic phase chronic myeloid leukemia. Hematology. Educational and program book of the 11 congress of EHA. Amsterdam, June 1518, 2006. p. 93—7.
2. Talpaz M., Silver R.T., Druker B.J. et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002;99:1928—37.
3. Kantarjian H., Talpaz M., O'Brien S. et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 2004;103:2873—8.
4. Aoki E., Kantarjian H., O'Brien S. et al. High-dose imatinib mesylate treatment in patients with untreated early chronic phase chronic myeloid leukemia. J Clin Oncol 2006;24:345s (abstr 6535).
5. Cortes J., Giles F., Salvado A. et al. High-dose imatinib in patients with previously untreated chronic myeloid leukemia in early chronic phase: preliminary results of a multicenter community based trial. J Clin Oncol 2005;23:564s (abstr 6518).
6. Guilhot F.G., Roy L., Millot F. Update of first-line in chronic phase chronic myeloid leukemia. Hematology. Educational and program book of the 11 congress of EHA. Amsterdam, June 1518, 2006. p. 93—7.
7. Coutre P., Gattermann N., O'Brien S.G. et al. A phase II study of nilotinib (AMN), a novel inhibitor BCR-ABL administered to imatinib resistant and intolerant patients with chronic myeloid leukemia in chronic phase. Hematology. Educational and program book of the 11 congress of EHA. Amsterdam, June 15-18, 2006. p. 377 (abstr 1028).
8. O'Hare T., Walters D.K., Stoffregen E.P. et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005;65:4500—5.
9. Kantarjian H., Ottmann O.G., Cortes J. et al. AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has significant activity in imatinib-resist-ant bcr-abl positive chronic myeloid leukemia. J Clin Oncol 2005;23:195s (abstr 3014).
10. Talpaz M., Rousselot P., Kim D.W. et al. A phase II study of dasatinib in patients with chronic myeloid leukemia (CML) in myeloid blast crisis who are resistant or intolerant to imatinib: first results of the CA180006 'START-B' study. Blood 2005;106:abstr 40.
11. Guilhot F., Apperley J.F., Shah N. et al. A phase II study of dasatinib in patients with accelerated phase chronic myeloid leukemia (CML) who are resistant or intolerant to imatinib: first results of the CA180005 'START-A' study. Blood 2005;106:abstr 39.
12. Hochhaus A., Baccarani M., Sawyers C. et al. Efficacy of dasatinib in patients with chronic phase philadelphia chromosome-positive CML resistant or intolerant to imatinib: first results of the CA180013 'START-C' phase II study. Blood 2005;106:abstr 41.
13. Copland M., Heany N., Stewart K. et al. Dasatinib (BMS-354825) has increased activity against Bcr-Abl compared to imatinib in primary CML cells in vitro, but does not eradicate quiescent CML stem cells. Blood 2005;1006:205a.
14. Golas J.M., Arndt K. Etienne C. et al. SKI-606, a 4-anilino-3-quinolinecar-bonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res 2003;63:375—81.
15. Kimura S., Naito H., Segawa H. et al. NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood 2005;106:3948—54.
16. Carter T.A, Wodicka L.M., Shah N.P. et al. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci USA 2005;102:11011—6.
17. Pinilla-Ibarz J., Cathcart K., Korontsvit T. et al. Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses. Blood 2000;95:1781—7.
18. Cathcart K., Pinilla-Ibarz J., Korontsvit T. et al. A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia. Blood 2004;103:1037—42.
Рецензия
Для цитирования:
Международный форум по вопросам лечения хронического миелолейкоза. Онкогематология. 2007;(2):76-79. https://doi.org/10.17650/1818-8346-2007-0-2-76-79
For citation:
International CML forum. Oncohematology. 2007;(2):76-79. (In Russ.) https://doi.org/10.17650/1818-8346-2007-0-2-76-79
Просмотров:
784
Послать статью по эл. почте 